Spironolactone Tablet, Film Coated
Product Images NDC 16729-225

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 16729-225). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Spironolactone 100mg 100 Count)

This is a description of a medication called Spironolactone USP in tablet form. The tablets contain 100mg of the active ingredient NDG 16729-227-01. The medication should be stored at room temperature between 20° to 25°C (68° to 77°F) and protected from light. It is to be dispensed in tight, light-resistant, child-resistant containers. Manufacturing information is included for the Accord Healthcare company in Durham, NG 27703 and Infas Pharma Limited in Ahmedabad. No prescribing information is given.*

FDA Label Image

Principal Display Panel (Spironolactone 25mg 100 Count)

This is a description of Spironolactone tablets. Each tablet contains 25mg of Spironolactone USP. The tablets should be stored at 20° to 25°C (68° to 77°F) and protected from light. They should be dispensed in tight, light-resistant, child-resistant containers. Dosage and usage information should be obtained from the accompanying prescribing information. The tablets are manufactured by Intas Pharma Limited in Ahmedabad, India and are distributed by Accord Healthcare, Inc. with the label NDG 16729-225-01.*

FDA Label Image

Principal Display Panel (Spironolactone 50mg 100 Count)

This is a medication called Spironolactone, which comes in a film-coated tablet containing 50 mg of the active ingredient. The tablets should be stored between 20 to 25°C and protected from light in tight, light-resistant, and child-resistant containers. Dosage and usage information can be found in the accompanying prescribing information. The medication is manufactured by Intas Pharma Limited of Ahmedabad, India, and distributed by Accord Healthcare, Inc. This information is intended for use only by prescription from authorized healthcare providers.*

FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

This is a partial text containing only some statistical results. It appears to show the p-value (less than 0.001) obtained from a log-rank test performed on data possibly collected over several months. Hence, without more context or complete information, it is difficult to provide a more detailed description or analysis.*

FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

This is a table showing the effectiveness of Spironolactone compared to a placebo in a subgroup analysis. The table includes different dosages of the treatment measured in increments of 0.2 from 0.2 to 1.4. The effectiveness of the treatments is measured on a scale where positive values indicate Spironolactone is better and negative values indicate the placebo is better.*

FDA Label Image

Chemical Structure (Spironolactone Structure Image)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.